Esperion Therapeutics Inc banner

Esperion Therapeutics Inc
NASDAQ:ESPR

Watchlist Manager
Esperion Therapeutics Inc Logo
Esperion Therapeutics Inc
NASDAQ:ESPR
Watchlist
Price: 2.74 USD 4.18% Market Closed
Market Cap: $655m

Wall Street
Price Targets

ESPR Price Targets Summary
Esperion Therapeutics Inc

Wall Street analysts forecast ESPR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ESPR is 6.86 USD with a low forecast of 1.8 USD and a high forecast of 16.8 USD.

Lowest
Price Target
1.8 USD
34% Downside
Average
Price Target
6.86 USD
150% Upside
Highest
Price Target
16.8 USD
513% Upside
Esperion Therapeutics Inc Competitors:
Price Targets
ALKS
Alkermes Plc
26% Upside
LE
Lands End Inc
195% Upside

Revenue
Forecast

N/A
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

The compound annual growth rate of Esperion Therapeutics Inc's revenue for the next 3 years is 12%.

Operating Income
Forecast

N/A
Past Growth
32% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss
N/A
Past Growth
32% / Year
Estimated Growth
Estimates Accuracy
-4%
Average Miss

The compound annual growth rate of Esperion Therapeutics Inc's operating income for the next 3 years is 32%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-90%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ESPR's stock price target?
Price Target
6.86 USD

According to Wall Street analysts, the average 1-year price target for ESPR is 6.86 USD with a low forecast of 1.8 USD and a high forecast of 16.8 USD.

What is Esperion Therapeutics Inc's Revenue forecast?
Projected CAGR
12%

The compound annual growth rate of Esperion Therapeutics Inc's revenue for the next 3 years is 12%.

What is Esperion Therapeutics Inc's Operating Income forecast?
Projected CAGR
32%

The compound annual growth rate of Esperion Therapeutics Inc's operating income for the next 3 years is 32%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett